Ensysce regains Nasdaq compliance with equity requirement, common stock continues trading

Ensysce Biosciences, Inc.

Received notice on May 24, 2024 from Nasdaq of regained compliance with Listing Rule 5550(b)(1) equity requirement.
Common stock will continue trading on Nasdaq Capital Market tier; delisting risk removed for now.
Company must maintain all Nasdaq listing requirements going forward; no assurance of future compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.